ArticleFrontiers in immunology2022
Identification of Biomarkers Associated With CD8+ T Cells in Coronary Artery Disease and Their Pan-Cancer Analysis.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 21 citations in OpenAlex.
- The Relationship and Mechanism of CD27 with Coronary Atherosclerotic Heart Disease.Cardiovascular drugs and therapy · 2026Review
- CD8Nature reviews. Cardiology · 2026Review
- Development of immune-derived molecular markers for coronary heart disease via multimachine learning.iScience · 2026Article
- Integrative analysis of programmed cell death pathways reveals prognostic biomarkers and immune infiltration signatures in coronary artery disease.Journal of thoracic disease · 2025Article
- NLRP3 inflammasome expression affects immune cell infiltration and clinical prognosis inMolecular medicine reports · 2025Article
- Epigenetic control of T helper cells differentiation: a mechanistic insight into the association between acute leukemia and coronary artery disease.Medical oncology (Northwood, London, England) · 2025Article
- Bioinformatics-Based Exploration of the Ability of Ginkgetin to Alleviate the Senescence of Cardiomyocytes After Myocardial Infarction and Its Cardioprotective Effects.Journal of inflammation research · 2025Article
- Immunophenotyping identifies key immune biomarkers for coronary artery disease through machine learning.PloS one · 2025Article
- Methods in DNA methylation array dataset analysis: A review.Computational and structural biotechnology journal · 2024Review
- Identification of hub modules and therapeutic targets associated with CD8Scientific reports · 2024Article
- Identification of Endoplasmic Reticulum Stress-Related Biomarkers in Coronary Artery Disease.Cardiovascular therapeutics · 2024Article
- Use of Machine Learning for the Identification and Validation of Immunogenic Cell Death Biomarkers and Immunophenotypes in Coronary Artery Disease.Journal of inflammation research · 2024Article
- Unraveling the role of cancer-associated fibroblasts in B cell lymphoma.Frontiers in immunology · 2024Review
- Role of lipid metabolism gene KLF4 in osteoarthritis.Clinical rheumatology · 2024Article
- Identification and validation of biomarkers in membranous nephropathy and pan-cancer analysis.Frontiers in immunology · 2024Article
- Single-cell RNA-seq reveals T cell exhaustion and immune response landscape in osteosarcoma.Frontiers in immunology · 2024Article
- Identification of prognostic and diagnostic signatures for cancer and acute myocardial infarction: multi-omics approaches for deciphering heterogeneity to enhance patient management.Frontiers in pharmacology · 2023Article
- Coronary artery disease-associated immune geneFrontiers in cardiovascular medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To identify biomarkers associated with CD8+ T cells in coronary artery disease (CAD) and initially explore their potential role in the tumor immune microenvironment. Materials and Methods: CAD-related datasets GSE12288, GSE34198, and GSE66360, were downloaded from the GEO database. First, GSVA was performed based on the GSE12288 dataset. Then WGCNA analysis was performed to identify the most relevant module and candidate hub gene for CD8+ T cells, followed by GO and KEGG analysis of this module. Secondly, the relationship between candidate hub genes and CD8+ T cells was verified using GSE34198 and GSE66360, which led to the identification of hub genes. The relationship of hub genes with CD8+ T cells in cancer was analyzed using the TIMER database. Methylation analysis of hub genes was performed using the DiseaseMeth database. CAD, pan-cancer, pan-cell lines, and pan-normal tissues, correlations between hub genes. In addition, potential drugs and TFs associated with hub genes were predicted, and the ceRNA network was constructed. Finally, GSEA was performed separately for hub genes. Results: CAD was shown to be associated with immune response by GSVA analysis. WGCNA identified the blue module as most related to CD8+ T cells and identified nine candidate hub genes. The relevance of CAD to immunity was further confirmed by GO and KEGG analysis of the module. Two additional datasets validated and identified three hub genes (FBXO7, RAD23A, and MKRN1) that significantly correlated with CD8+ T cells. In addition, we found that hub genes were positively associated with CD8+ T cells in TGCT, THCA, and KICH cancers by our analysis. Moreover, the hub gene was differentially methylated. We also analyzed the correlation between hub genes in CAD, different cancers, different cell lines, and different normal tissues. The results of all the analyses showed a positive correlation between them. Finally, we successfully constructed hub gene-associated TF-gene and ceRNA networks and predicted 11 drugs associated with hub genes. GSEA suggests that hub genes are related to multiple immune response processes. Conclusion: FBXO7, RAD23A, and MKRN1 are significantly associated with CD8+ T cells in CAD and multiple cancers and may act through immune responses in CAD and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.